Rapport Therapeutics, Inc. Basic Shares Outstanding (Weighted Average)
Rapport Therapeutics, Inc. (RAPP) reported Basic Shares Outstanding (Weighted Average) of 47.47 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-05
- Rapport Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 47.47M shares, a 33.94% increase year-over-year.
- Rapport Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 47.24M shares, a 33.94% increase year-over-year.
- Rapport Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 47.07M shares, a 33.80% increase year-over-year.
- Rapport Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 37.93M shares, a 8.82% increase year-over-year.
- Rapport Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 38.93M shares, a 87.74% increase from fiscal 2024.
- Rapport Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 20.74M shares, a 1277.25% increase from fiscal 2023.
- Rapport Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 1.51M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 47.47M shares 10-Q · filed 2026-08-05 | 47.36M shares 10-Q · filed 2026-08-05 | 47.26M shares derived: average of 3 quarters · filed 2026-08-05 | 44.93M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 47.24M shares 10-Q · filed 2026-05-07 | 47.15M shares derived: average of 2 quarters · filed 2026-05-07 | 44.08M shares derived: average of 3 quarters · filed 2026-05-07 | 41.92M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | 47.07M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 42.50M shares derived: average of 2 quarters · filed 2026-03-10 | 40.15M shares derived: average of 3 quarters · filed 2026-08-05 | 38.93M shares 10-K · filed 2026-03-10 |
| 2025-09-30 | 37.93M shares 10-Q · filed 2025-11-06 | 36.69M shares derived: average of 2 quarters · filed 2026-08-05 | 36.22M shares 10-Q · filed 2025-11-06 | 35.95M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | 35.44M shares 10-Q · filed 2026-08-05 | 35.36M shares 10-Q · filed 2026-08-05 | 35.30M shares derived: average of 3 quarters · filed 2026-08-05 | 35.19M shares derived: average of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | 35.27M shares 10-Q · filed 2026-05-07 | 35.22M shares derived: average of 2 quarters · filed 2026-05-07 | 35.10M shares derived: average of 3 quarters · filed 2026-05-07 | 28.99M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 35.18M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 35.02M shares derived: average of 2 quarters · filed 2026-03-10 | 26.90M shares derived: average of 3 quarters · filed 2026-03-10 | 20.74M shares 10-K · filed 2026-03-10 |
| 2024-09-30 | 34.86M shares 10-Q · filed 2025-11-06 | 22.76M shares derived: average of 2 quarters · filed 2025-11-06 | 15.93M shares 10-Q · filed 2025-11-06 | 12.31M shares derived: average of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | 10.67M shares 10-Q · filed 2025-08-07 | 6.36M shares 10-Q · filed 2025-08-07 | 4.80M shares derived: average of 3 quarters · filed 2025-08-07 | 3.98M shares derived: average of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | 2.05M shares 10-Q · filed 2025-05-08 | 1.87M shares derived: average of 2 quarters · filed 2025-05-08 | 1.76M shares derived: average of 3 quarters · filed 2025-05-08 | 1.68M shares derived: average of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | 1.69M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | 1.61M shares derived: average of 2 quarters · filed 2025-03-11 | 1.55M shares derived: average of 3 quarters · filed 2025-03-11 | 1.51M shares 10-K · filed 2025-03-11 |
| 2023-09-30 | 1.53M shares 10-Q · filed 2024-11-07 | 1.48M shares derived: average of 2 quarters · filed 2024-11-07 | 1.44M shares 10-Q · filed 2024-11-07 | |
| 2023-06-30 | 1.44M shares 10-Q · filed 2024-08-08 | 1.40M shares 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |